Efficient in vitro cleavage of mouse acute phase serum amyloid a mRNA mediated by a synthetic hammerhead ribozyme

Scandinavian Journal of Immunology

Volumn 46, Issue 1, 1997, Pages 51-58

  Gaughan, D J ^a   Whitehead, A S ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; MESSENGER RNA; RIBOZYME; SERUM AMYLOID A;

AMYLOIDOSIS; ARTICLE; COMPUTER ANALYSIS; IMMUNOGENETICS; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; RNA CLEAVAGE; RNA STRUCTURE; STRUCTURE ANALYSIS;

EID: 0030792086     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-97.x     Document Type: Article

References (38)

1. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988;334:585-92.
2. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328:596-600.
3. Koizumi M, Hayase Y, Iwai S, Kamiya H, Inoue H, Ohtsuka E. Designing of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res 1989;17:7059-71.
4. Saxena SK, Ackerman EJ. Ribozymes correctly cleave a model substrate and endogenous RNA in vivo. J Biol Chem 1990;265: 17106-9.
5. L'Huilier PJ, Davis SR, Bellamy RA. Cytoplasmic delivery of ribozymes leads to efficient reduction in α-lactalbumin mRNA levels in C1271 mouse cells. EMBO J 1992;11:4411-18.
6. Cantor GH, McElwain TF, Birkebak TA, Palmer GH. Ribozyme cleaves rex/tax messenger RNA and inhibits bovine leukemia virus expression. Proc Natl Acad Sci USA 1993;90:10932-6.
7. Yu M, Poeschla E, Wong-Staal F. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Gene Therapy 1993;1:13-26.
8. Hind, C. Amyloidosis and Amyloid P component. Longman, 1986.
9. Sipe JD, McAdam KPWJ, Uchino F. Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest 1978;38:110-14.
10. Kivilesky R. Amyloidosis: a familiar problem in the light of current pathogenic development. Lab Invest 1983;49:381-90.
11. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985;21:283-7.
12. Steel DM, Whitehead AS. The major acute phase reactants; C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology Today 1994;15:81-8.
13. Marhaug G. Three assays for the characterization and quantitation of human serum amyloid A. Scand J Immunol 1983;18:329-38.
14. Steel DM, Whitehead AS. Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1β and interleukin-6 in the human hepatoma cell line PLC/PRF/5. Biochem J 1991;277: 477-82.
15. Uhlar CM, Burgess CJ, Sharp PM, Whitehead AS. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 1994;19: 228-35.
16. Uhlar CM, Black IJ, Shields DC et al. Wallaby serum amyloid A protein: cDNA cloning, sequence and evolutionary analysis. Scand J Immunol 1996;43:271-6.
17. Mitchell TI, Coon CI, Brickerhoff CE. Serum amyloid A (SAA3) produced by rabbit synovial fibroblasts treated with phorbol esters or interleukin-1 induces synthesis of collagenase and is neutralised with specific antiserum. J Clin Invest 1991;87:1177-85.
18. Xu L, Badolato R, Murphy WJ et al. A novel biologic function of serum amyloid A: induction of T lymphocyte migration and adhesion. J Immunol 1995;155:1185-90.
19. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest 1987;66:778-85.
20. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3: density, size and apolipoprotein composition. J Biol Chem 1986;261:9644-51.
21. Steinmetz A, Hocke G, Saile R, Puchois P, Fruchart JC. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochem Biophys Acta 1989;1006:173-8.
22. Shiroo M, Kawahara E, Nakanishi I, Migita S. Specific deposition of serum amyloid A protein 2 in mouse. Scand J Immunol 1987;26: 709-16.
23. Butler A, Whitehead AS. Mapping of the mouse serum amyloid A, Saa, gene cluster by long range polymerase chain reaction. Immunogenetics 1996;44:468-74.
24. 2-terminal sequence identity with one of two serum amyloid protein (apo SAA) gene products. J Exp Med 1984;159:641-6.
25. Gaughan DJ, Steel DM, Whitehead AS. Ribozyme mediated cleavage of acute phase serum amyloid A (A-SAA) mRNA in vitro. FEBS Lett 1995;374:241-5.
26. Zuker M, Stiegler R. Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res 1981;9:133-48.
27. Yamamoto K, Migita S. Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences. Proc Natl Acad Sci USA 1985;82:2915-19.
28. Heidenreich O, Eckstein F. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J Biol Chem 1992;267:1904-9.
29. Hendrix C, Anne J, Joris B et al. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem J 1996;314:655-61.
30. Shimayama T, Nishikawa S, Taira K. Generality of the NUX rule: kinetic analysis of the results of systematic mutations in the tri-nucleotide at the cleavage site of hammerhead ribozymes. Biochemistry 1995;34:3649-54.
31. Xing Z, Whitton J. Ribozymes which cleave arenavirus RNAs: identification of susceptible target sites and inhibition by target site secondary structure. J Virol 1992;66:1361-9.
32. Bertrand E, Pictet R, Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res 1994;22:293-9.
33. Pyle AM. Ribozymes: A distinct class of metalloenzymes. Science 1993;261:709-14.
34. Steitz TA, Steitz JA. A general two-metal-ion mechanism for catalytic RNA. Proc Natl Acad Sci USA 1993;90:6498-502.
35. Orita M, Vinayak R, Andrus A et al. Magnesium-mediated conversion of an inactive form of a hammerhead ribozyme to an active complex with its substrate. J Biol Chem 1996;271:9447-54.
36. Furuichi Y, La Fiandra A, Shatkin AJ. 5′-Terminal structure and mRNA stability. Nature 1977;266:235-9.
37. Bernstein P, Ross J. Poly(A), poly(A) binding protein and the regulation of mRNA stability. Trends Biochem Sci 1989;14:373-7.
38. Grehan S, Uhlar CM, Sim RB, Herbert J, Whitehead AS. Expression of a biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response. J Immunol 1997; in press.